Evidence Snapshot

Potassium-transporting ATPase

CHEMBL2095173 PROTEIN COMPLEX Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:04:46Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 7:04 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2095173

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Potassium-transporting ATPase as ChEMBL target CHEMBL2095173, mapped to UniProt P20648. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Potassium-transporting ATPase

PROTEIN COMPLEX · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2095173

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P20648

Potassium-transporting ATPase alpha chain 1

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Potassium-transporting ATPase matters

As of 2026-09-13

Potassium-transporting ATPase is reviewed as Potassium-transporting ATPase alpha chain 1 (UniProt P20648); Potassium-transporting ATPase shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block.; 13 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 336 compounds, and 17 assays, with lead potency reaching pChEMBL 7.7.

Protein context

Potassium-transporting ATPase alpha chain 1

Potassium-transporting ATPase alpha chain 1 Sequence length is 1035 aa.

Review this target as Potassium-transporting ATPase, mapped to UniProt P20648. ChEMBL maps the protein component as Potassium-transporting ATPase alpha chain 1. Sequence length is 1035 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P20648 Protein

Disease context

gastroesophageal reflux disease

Potassium-transporting ATPase shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block. 13 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABEPRAZAN, DEXLANSOPRAZOLE, ESOMEPRAZOLE MAGNESIUM.

Start review with gastroesophageal reflux disease because it currently carries approved-linked support. Linked drugs include ABEPRAZAN, DEXLANSOPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 13 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 336 compounds, and 17 assays for this target. The dominant activity type is IC50. CHEMBL1202672 is the current potency anchor at pChEMBL 7.7.

Use CHEMBL1202672 as the tractability anchor when discussing potency (pChEMBL 7.7).

Activity source · ChEMBL 36 via Core Engine

5 approved pChEMBL 7.7

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Potassium-transporting ATPase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P20648, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why gastroesophageal reflux disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

336

Total Compounds

Total Assays

Approved Drugs

IC50: 327.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL1202672	7.7	IC50	—
No preferred name CHEMBL1202661	7.5	IC50	—
No preferred name CHEMBL1790041	7.4	IC50	Approved
No preferred name CHEMBL1202621	7.3	IC50	—
No preferred name CHEMBL1202647	7.3	IC50	—